Federal Judge Rejects FDA Bid to Dismiss Niagen Challenge

Share

A federal judge has denied FDA's motion to dismiss a lawsuit challenging the agency's decision to allow nicotinamide mononucleotide (NMN), an ingredient used in anti-aging products, to be marketed as a dietary supplement rather than regulated as a drug.

In an 11/19 memorandum opinion, U.S. district judge Amir H. Ali ruled that Niagen Bioscience has standing to challenge FDA's 9/2025 reversal of its interpretation of federal dietary supplement law.

Niagen, which markets products containing the NAD+ precursor nicotinamide riboside, argues that FDA's decision unlawfully permitted competing NMN products to enter the dietary supplement market.

The company presented evidence that its year-over-year sales growth declined, and Ali found that the company had demonstrated sufficient competitive injury to pursue its claims and rejected the government's argument that Niagen's interests fell outside the protections of the relevant statute.

The ruling allows Niagen's lawsuit to proceed but does not resolve whether FDA's interpretation of the dietary supplement law was lawful.

Read more